Abstract: Process for converting a dinitrile to a diamine and optionally an aminonitrile, in which a Group VIII element catalyst is treated with a modifier either before or during a substantially solvent-free hydrogenation reaction in which the dinitrile is contacted with hydrogen in the presence of the catalyst.
Type:
Grant
Filed:
May 31, 2001
Date of Patent:
April 23, 2002
Assignee:
E. I. du Pont de Nemours and Company
Inventors:
Alan M. Allgeier, Theodore A. Koch, Sourav K. Sengupta
Abstract: A process for the treatment of aqueous waste streams having a pH of 5 to 11 and containing organoboron compounds of the formula R4B−1M+ with hydrogen peroxide in order to convert such organoboron compounds to boric acid and organic compounds.
Abstract: A process for making 6-aminocaproic acid by hydroformylating 3-pentenenitrile to produce 3-, 4-, and 5-formylvaleronitrile (FVN mixture), oxidizing the FVN mixture to produce 3-, 4-, and 5-cyanovaleric acid; hydrogenating the resulting product to produce 6-aminocaproic acid, 5-amino-4-methylvaleric acid, and 4-amino-3-ethylbutyric acid; and isolating 6-aminocaproic acid from the reaction product. The resulting 6-aminocaproic acid can be cyclized to produce caprolactam.
Type:
Grant
Filed:
November 16, 2000
Date of Patent:
April 16, 2002
Assignee:
E.I. du Pont de Nemours and Company
Inventors:
Emilio E. Bunel, Theodore A. Koch, Ronnie Ozer, Sourav K. Sengupta
Abstract: The invention relates to monoclonal anti-idiotypic antibodies to human anti-DNA antibodies. Monoclonal, anti-idiotypic antibodies are produced using hybridoma technology. The antibodies are used as diagnostic reagents in methods to determine the presence of anti-native DNA antibodies in serum from patients suspected of having systemic lupus erythematosus.
Abstract: A method for the rapid detection of virus and viral antigens associated with somatic cells in biological test samples is disclosed. The method comprises lysing the cells with a lytic agent to reveal virus or viral antigens for participation in a virus detection system. The lytic agent is chosen for its biological neutrality in the detection system, particularly its inability to produce a cytopathic effect in tissue culture.
Type:
Grant
Filed:
September 29, 1983
Date of Patent:
April 8, 1986
Assignees:
E. I. Du Pont de Nemours and Company, Board of Trustees
Abstract: A heterogeneous immunoassay for digoxin. An excess of labeled anti-digoxin antibody is added to a test sample and the resulting reaction mixture is contacted with a solid phase having ouabain immobilized thereon. All the free, labeled antibody binds to the oubain. The eluted digoxin anti-digoxin antibody complex is measured for label activity. A competitive mode is also disclosed.